Last Updated : May 3, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| N/A | eltrombopag | Severe Aplastic Anemia (SAA) | Reimburse with clinical criteria and/or conditions | Active | ||
| Awiqli | insulin icodec | Diabetes mellitus, type 2 | Active | |||
| Orgovyx | relugolix | Advanced prostate cancer | Active | |||
| Elrexfio | elranatamab | Relapsed or refractory multiple myeloma | Active | |||
| Ultomiris | ravulizumab | Neuromyelitis optica spectrum disorder (NMOSD) | Reimburse with clinical criteria and/or conditions | Active | ||
| Uplizna | inebilizumab | Neuromyelitis optica spectrum disorders (NMOSD) | Reimburse with clinical criteria and/or conditions | Active | ||
| Ikervis | cyclosporine | keratitis, severe | Withdrawn | |||
| Breo Ellipta | fluticasone furoate/vilanterol | COPD | Withdrawn | |||
| TBD | Cabozantinib | Withdrawn | ||||
| Iluvien | fluocinolone acetonide | Diabetic macular edema (DME) | Withdrawn |
Last Updated : May 3, 2024